<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251651/" ref="ordinalpos=744&amp;ncbi_uid=4479909&amp;link_uid=PMC3251651" image-link="/pmc/articles/PMC3251651/figure/F4/" class="imagepopup">Fig. 4. OTEs and off-targets of raloxifene, tamoxifen, paclitaxel, and fulvestrant on the cell cycle G1/S checkpoint and P53 <span class="highlight" style="background-color:">signaling</span> pathways.  From: A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. </a></div><br /><div class="p4l_captionBody">The right side is for the signal cascade in the cell cycle G1/S checkpoint signaling pathway while the left side is for the P53 signaling pathway. The drug-dose pairs are listed in the middle. The drug-targeted pathway was generated using IPA software (Ingenuity Systems, Inc. Redwood City, CA).</div></div>